| Ytd | -47.64% | |
| 1y | -47.98% |
| Open | 3.23 | Prev Close | 3.25 | Low | 3.15 | High | 3.27 | Mkt Cap | 304.12M |
| Vol | 0.00 | Avg Vol | 1.93M | EPS | -0.13 | P/E | -24.77 | Forward P/E | 71.53 |
| Beta | 1.89 | Short Ratio | 4.83 | Inst. Own | 103.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 4.95 | 200-d Avg | 5.45 | 1yr Est | 19.41 |
MYGN News
Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free R
Myriad Genetics (MYGN) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Au
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughl
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation fi
LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Str
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating pot
NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Ge
Myriad Genetics Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just t
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a
Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollou
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los